1.Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Chunde BAO ; Shunle CHEN ; Yueying GU ; Zhiying LAO ; Liqing NI ; Qiang YU ; Jianhua XU ; Xiangpei LI ; Jialing LIU ; Lingyun SUN ; Peigen HE ; Jiliang MA ; Shuyun XU ; Changhai DING
Chinese Medical Journal 2003;116(8):1228-1234
OBJECTIVETo evaluate the efficacy and safety of leflunomide in comparison with methotrexate (MTX) on patients with rheumatoid arthritis (RA) in China.
METHODSFive hundred and sixty-six patients with active rheumatoid arthritis were randomly assigned to receive leflunomide at 20 mg once daily or MTX at 15 mg once weekly in a controlled trial. Five hundred and four patients completed the 12-week treatment and some patients continued the treatment for 24 weeks.
RESULTSBoth leflunomide and MTX could improve the symptoms, signs, and joint function, but there were no changes in X-ray observations of patients with rheumatoid arthritis. In the leflunomide group, the overall rates of effectiveness at 12 weeks and 24 weeks were 86.94% and 92.31% respectively; the rates of remarkable improvement were 64.95% and 79.81% respectively. In the MTX group, the overall rates of effectiveness at 12 weeks and 24 weeks were 84.04% and 83.15% respectively; the rates of remarkable improvement were 56.81% and 75.28% respectively. According to intent-to-treat analysis, the ACR 20% response rates at 12 weeks and 24 weeks in the leflunomide group were 62.54% and 67.18% respectively, compared with 60.08% and 61.32% respectively in MTX group. No statistical differences were shown in the efficacy between the two groups (P > 0.05). The adverse events in the leflunomide group were gastrointestinal symptoms, skin rash, alopecia, nervous system symptoms, decreased leukocyte count, and elevation of alanine aminotransferase (ALT). Most of these side effects were mild and transient. The incidence of adverse events in the leflunomide group was 16.84%, significantly lower than that in MTX group (28.17%, P = 0.002).
CONCLUSIONSLeflunomide is effective in the treatment of RA with less adverse events than MTX. Its efficacy is similar to MTX, but the incidence of adverse events and the rate of withdrawal due to adverse events were lower in the leflunomide group than in MTX group.
Antirheumatic Agents ; adverse effects ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Female ; Growth Inhibitors ; adverse effects ; therapeutic use ; Humans ; Immunosuppressive Agents ; adverse effects ; therapeutic use ; Isoxazoles ; adverse effects ; therapeutic use ; Male ; Methotrexate ; adverse effects ; therapeutic use ; Middle Aged
2.Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Liang-jing LÜ ; Jia-lin TENG ; Chun-de BAO ; Xing-hai HAN ; Ling-yun SUN ; Jiang-hua XU ; Xing-fu LI ; Hua-xiang WU
Chinese Medical Journal 2008;121(7):615-619
BACKGROUNDA novel anti-rheumatic drug, T-614, has been shown to have an anti-inflammatory effect and to improve abnormal immunological findings in rheumatoid arthritis (RA). To assess the safety and efficacy of T-614 versus placebo in patients with active RA we conducted a 24-week clinical study in 280 Chinese patients.
METHODSIn a multicenter, randomized, double blind, placebo controlled study, 280 patients were randomly assigned to receive placebo (n = 95) or T-614 at 50 mg (n = 93) or 25 mg (n = 92) daily. Active disease was defined by 4 of the following 5 criteria: >or= 5 tender joints, >or= 3 swollen joints, morning stiffness lasting for >or= 60 minutes, and Westergren erythrocyte sedimentation rate (ESR) >or= 28 mm/h, the assessment of pain at the rest by patient as moderate or severe. Clinical and laboratory parameters were analyzed at baseline, 2, 4, 6, 12, 18 and 24 weeks. The primary efficacy variable at week 24 was the American College of Rheumatology (ACR) response rate using the intent-to-treat population.
RESULTSThe ACR response rate was significantly higher in the T-614 treatment group compared with the placebo group within 8 weeks after the initiation of treatment. After 24 weeks, the 25 mg/d and 50 mg/d dosage groups and the placebo group showed 39.13%, 61.29% and 24.21% in ACR20 and 23.91%, 31.18% and 7.37% in ACR50, respectively. A time-response in ACR response was observed, with clear superiority for the 25 mg/d and 50 mg/d dosage groups compared to placebo (P < 0.0001), and the 50 mg/d dose compared to the 25 mg/d dose (P < 0.05) when using the ACR response analyses after 24 weeks. ESR and c-reactive protein (CRP) were significantly different in the treatment groups after 24 weeks. The incidence of adverse events (AEs) was not significantly higher with T-614 than with placebo, but upper abdominal discomfort, leucopenia, elevated serum alanine aminotransferase (sALT), skin rash and/or pruritus were more common in the 50 mg and 25 mg dosage groups.
CONCLUSIONT-614, a new slow-acting drug, is effective in treatment of rheumatoid arthritis and is well tolerated.
Adult ; Aged ; Antirheumatic Agents ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Benzopyrans ; adverse effects ; therapeutic use ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Sulfonamides ; adverse effects ; therapeutic use
3.Clinical trials of integrative medicine for rheumatoid arthritis: Issues and recommendations.
Chi ZHANG ; Miao JIANG ; Xiao-Juan HE ; Ai-Ping LU
Chinese journal of integrative medicine 2015;21(6):403-407
Controlled clinical trials of integrative therapies available to patients with rheumatoid arthritis (RA) improved dramatically in the past 20 years, largely because of the growing need and the methodologies improvement. Tripterygium wilfordii Hook. F., a typical example of popular use herb, has been extensively studied in trials. However, clear and convincing evidence of integrative therapy, effectiveness and safety, remains insufficient to make decision. Many research efforts are hampered by standing problems with 'syndrome' recruitment failure. In addition, the outcome multiplicity induces the findings inefficiency to generalize to RA patients at large. Development of validated syndrome outcomes and methodologies has also been critical. Current efforts to enhance the understanding of integrative treatment options for patients with RA include the development of drug-specific rather than disease-specific strategies, studies in predictive biomarkers, and development of peer-review trial protocol for regular clinical trials.
Antirheumatic Agents
;
adverse effects
;
therapeutic use
;
Arthritis, Rheumatoid
;
drug therapy
;
Clinical Trials as Topic
;
Humans
;
Integrative Medicine
;
Tripterygium
;
chemistry
4.Retrospective study of adverse events in patients with rheumatoid arthritis treated with second-line drugs.
Lindi JIANG ; Naiqing ZHAO ; Liqing NI
Chinese Journal of Epidemiology 2002;23(3):213-217
OBJECTIVETo evaluate rates on the adverse side effect and discontinuation of second-line drugs frequently used in the treatment of rheumatoid arthritis (RA).
METHODEight hundred and sixty-four RA patients were studied in a retrospective program.
RESULTSUpper abdominal discomfort was most commonly seen when using second-line drugs. Rash was often associated with D-penicillamine (20.6%) and Sinomenium therapy (13.7%). Methotrexate (MTX) was uniquely characterized by substantial upper GI toxicity (32.2%) and Tripterygium wilfordii Hook. f. (TWH) (14.4%) by menstrual abnormality. Sulfasalazine users reported adverse events including upper abdominal trouble (39.0%), nausea (7.3%) and anorexia (7.3%) while the risk of GI malaise was greater. Patients taking hydroxychloroquine complained of blurred vision (19.6%) but no one went blind. Toxic side effects seemed to be the most common reasons for stoppages, and the patients taking MTX had the lowest discontinuation rate. Combination of D-penicillamine and Methotrexate did not increase the incidence of adverse events.
CONCLUSIONSKnowledge on these different patterns of toxicity provided choices in the selection of second line agents for particular RA patients. However, long-term monitor are required when drugs are being used.
Adult ; Anorexia ; chemically induced ; Antirheumatic Agents ; adverse effects ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Exanthema ; chemically induced ; Female ; Gastrointestinal Diseases ; chemically induced ; Humans ; Hydroxychloroquine ; adverse effects ; therapeutic use ; Male ; Methotrexate ; adverse effects ; therapeutic use ; Middle Aged ; Nausea ; chemically induced ; Penicillamine ; adverse effects ; therapeutic use ; Phytotherapy ; Plant Preparations ; adverse effects ; therapeutic use ; Retrospective Studies ; Sinomenium ; Sulfasalazine ; adverse effects ; therapeutic use
5.Safe Re-administration of Tumor Necrosis Factor-alpha (TNFalpha) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFalpha Therapy.
Young Sun SUH ; Seung Ki KWOK ; Ji Hyeon JU ; Kyung Su PARK ; Sung Hwan PARK ; Chong Hyeon YOON
Journal of Korean Medical Science 2014;29(1):38-42
There is no consensus on whether it is safe to re-administer tumor necrosis factor-alpha (TNFalpha) inhibitors in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) flared after withdrawal of TNFalpha inhibitors due to active tuberculosis (TB). We evaluated the safety of restarting anti-TNFalpha therapy in patients with TNFalpha-associated TB. We used data of 1,012 patients with RA or AS treated with TNFalpha inhibitors at Seoul St. Mary's Hospital between January 2003 and July 2013 to identify patients who developed active TB. Demographic and clinical data including the results of tuberculin skin tests (TST) and interferon-gamma releasing assays (IGRA) were collected. Fifteen patients developed active TB. Five cases were occurred in RA and 10 cases in AS. Nine of 15 patients had a negative TST or IGRA and 6 TST-positive patients had received prophylaxis prior to initiating anti-TNFalpha therapy. All patients discontinued TNFalpha inhibitors with starting the treatment of TB. Eight patients were re-administered TNFalpha inhibitors due to disease flares and promptly improved without recurrence of TB. TNFalpha inhibitors could be safely resumed after starting anti-TB regimen in patients with RA or AS.
Adult
;
Aged
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
;
Antibodies, Monoclonal/adverse effects/therapeutic use
;
Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use
;
Antirheumatic Agents/adverse effects/therapeutic use
;
Arthritis, Rheumatoid/*drug therapy
;
Enzyme Inhibitors/adverse effects/therapeutic use
;
Female
;
Humans
;
Hydroxychloroquine/adverse effects/therapeutic use
;
Immunoglobulin G/adverse effects/therapeutic use
;
Immunosuppressive Agents/adverse effects/*therapeutic use
;
Interferon-gamma Release Tests
;
Male
;
Methotrexate/adverse effects/therapeutic use
;
Middle Aged
;
Mycobacterium tuberculosis/isolation & purification
;
Receptors, Tumor Necrosis Factor/therapeutic use
;
Retrospective Studies
;
Spondylitis, Ankylosing/*drug therapy
;
Tuberculin Test
;
Tuberculosis/*chemically induced/microbiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
6.Treatment failure with disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
Niti MITTAL ; Rakesh MITTAL ; Aman SHARMA ; Vinu JOSE ; Ajay WANCHU ; Surjit SINGH
Singapore medical journal 2012;53(8):532-536
INTRODUCTIONRheumatoid arthritis (RA) patients taking disease-modifying antirheumatic drugs (DMARDs) may experience treatment failure due to adverse effects or a lack of efficacy/resistance. The purpose of this study was to evaluate the prescription patterns, the incidence and reasons for failure, and the time to treatment failure of DMARDs in RA patients.
METHODSThe medical records of patients visiting the Rheumatology Clinic were scrutinised retrospectively in order to extract the relevant data, including demographics, clinical and laboratory investigations and drug usage, for analysis.
RESULTSMore than 60% of the 474 eligible patients were started on a combination of DMARDs. Hydroxychloroquine (HCQ) (79.7%) and methotrexate (MTX) (55.6%) were the most common DMARDs prescribed initially. There was a significant difference in survival times among the various treatment groups (p ≤ 0.001). Adverse effect was the main reason for treatment failure of sulfasalazine (SSZ) (88.9%) and MTX (75%), while addition or substitution DMARDs was more common for those taking HCQ (72.2%). Adverse event was reported as the most significant predictor of treatment failure. The most commonly reported adverse effects were bone marrow suppression and hepatotoxicity.
CONCLUSIONA combination of DMARDs was used to initiate therapy in more than 60% of RA patients, with HCQ and MTX being prescribed most frequently. Adverse effects accounted mainly for treatment failures with MTX and SSZ, while lack of efficacy was responsible for major treatment failures with HCQ.
Adult ; Antirheumatic Agents ; adverse effects ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Drug Therapy, Combination ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Retrospective Studies ; Treatment Failure
7.Development of Crescentic Immunoglobulin A Nephritis and Multiple Autoantibodies in a Patient during Adalimumab Treatment for Rheumatoid Arthritis.
Xia LI ; Jie MA ; Yan ZHAO ; Hai-Yun WANG ; Xue-Mei LI
Chinese Medical Journal 2015;128(18):2555-2556
Adalimumab
;
adverse effects
;
therapeutic use
;
Antirheumatic Agents
;
adverse effects
;
therapeutic use
;
Arthritis, Rheumatoid
;
drug therapy
;
immunology
;
Asian Continental Ancestry Group
;
Autoantibodies
;
immunology
;
Female
;
Humans
;
Immunoglobulin A
;
immunology
;
Middle Aged
;
Nephritis
;
etiology
;
immunology
8.Methimazole-Induced Bullous Systemic Lupus Erythematosus: A Case Report.
Ji Yeon SEO ; Hee Jin BYUN ; Kwang Hyun CHO ; Eun Bong LEE
Journal of Korean Medical Science 2012;27(7):818-821
Bullous systemic lupus erythematosus (SLE) is a kind of LE-non-specific bullous skin disease that is rarely induced by a medication. We describe the first case of bullous SLE to develop after administration of methimazole. A 31-yr-old woman presented with generalized erythematous patches, multiple bullae, arthralgia, fever, conjunctivitis, and hemolytic anemia. Biopsy of her bulla showed linear deposition of lgG, lgA, C3, fibrinogen, and C1q at dermo-epidermal junction. She was diagnosed as bullous SLE and treated with prednisolone, dapsone, hydroxychloroquine, and methotrexate. Our experience suggests that SLE should be considered as a differential diagnosis when bullous skin lesions develop in patients being treated for hyperthyroidism.
Adult
;
Anti-Inflammatory Agents/therapeutic use
;
Antirheumatic Agents/therapeutic use
;
Antithyroid Agents/*adverse effects/therapeutic use
;
Blister/chemically induced/pathology
;
Drug Therapy, Combination
;
Female
;
Graves Disease/diagnosis/drug therapy
;
Humans
;
Hydroxychloroquine/therapeutic use
;
Immunosuppressive Agents/therapeutic use
;
Lupus Erythematosus, Systemic/chemically induced/*diagnosis/drug therapy
;
Lupus Nephritis/diagnosis/drug therapy
;
Methimazole/*adverse effects/therapeutic use
;
Mycophenolic Acid/analogs & derivatives/therapeutic use
;
Prednisolone/therapeutic use
;
Skin/pathology
9.Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
Gwan Gyu SONG ; Sang Cheol BAE ; Young Ho LEE
The Korean Journal of Internal Medicine 2014;29(5):656-663
BACKGROUND/AIMS: The aim of this study was to assess the efficacy and safety of tofacitinib (5 and 10 mg twice daily) in patients with active rheumatoid arthritis (RA). METHODS: A systematic review of randomized controlled trials (RCTs) that examined the efficacy and safety of tofacitinib in patients with active RA was performed using the Medline, Embase, and Cochrane Controlled Trials Register databases as well as manual searches. RESULTS: Five RCTs, including three phase-II and two phase-III trials involving 1,590 patients, met the inclusion criteria. The three phase-II RCTs included 452 patients with RA (144 patients randomized to 5 mg of tofacitinib twice daily, 156 patients randomized to 10 mg of tofacitinib twice daily, and 152 patients randomized to placebo) who were included in this meta-analysis. The American College of Rheumatology 20% response rate was significantly higher in the tofacitinib 5- and 10-mg groups than in the control group (relative risk [RR], 2.445; 95% confidence interval [CI], 1.229 to 4.861; p = 0.011; and RR, 2.597; 95% CI, 1.514 to 4.455; p = 0.001, respectively). The safety outcomes did not differ between the tofacitinib 5- and 10-mg groups and placebo groups with the exception of infection in the tofacitinib 10-mg group (RR, 2.133; 95% CI, 1.268 to 3.590; p = 0.004). The results of two phase-III trials (1,123 patients) confirmed the findings in the phase-II studies. CONCLUSIONS: Tofacitinib at dosages of 5 and 10 mg twice daily was found to be effective in patients with active RA that inadequately responded to methotrexate or disease-modifying antirheumatic drugs, and showed a manageable safety profile.
Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use
;
Arthritis, Rheumatoid/*drug therapy
;
Clinical Trials, Phase II as Topic
;
Clinical Trials, Phase III as Topic
;
Humans
;
Janus Kinases/antagonists & inhibitors
;
Methotrexate/therapeutic use
;
Piperidines/administration & dosage/adverse effects/*therapeutic use
;
Protein Kinase Inhibitors/administration & dosage/adverse effects/therapeutic use
;
Pyrimidines/administration & dosage/adverse effects/*therapeutic use
;
Pyrroles/administration & dosage/adverse effects/*therapeutic use
;
Randomized Controlled Trials as Topic
;
Treatment Outcome
10.The use of biological agents in the treatment of rheumatoid arthritis.
Peng Thim FAN ; Keng Hong LEONG
Annals of the Academy of Medicine, Singapore 2007;36(2):128-134
Rheumatoid arthritis is a common and potentially devastating condition which did not have good treatment options until recently. Pharmacological treatment should not just comprise antiinflammatory agents and corticosteroids. The current therapeutic approach is to start a disease modifying agent early in the illness to prevent eventual joint damage. Older disease modifying anti-rheumatic drugs (DMARDs) include methotrexate, sulphasalazine and hydroxychloroquine. Newer ones such as leflunomide and cyclosporine are also used. A recent advance in the management of rheumatoid arthritis is the use of biological agents which block certain key molecules involved in the pathogenesis of the illness. They include tumour necrosis factor (TNF)- blocking agents such as infliximab, etanercept and adalimumab, the anti-CD 20 agent rituximab and CTLA-4 Ig abatacept. Other agents which are in development include anti-IL6 tocilizumab, anti-CD22 and anti-lymphostat B. In this review, the efficacy and side effects of these agents, their impact on current clinical practice and future trends are discussed.
Abatacept
;
Antibodies, Monoclonal
;
therapeutic use
;
Antibodies, Monoclonal, Humanized
;
Antirheumatic Agents
;
therapeutic use
;
Arthritis, Rheumatoid
;
immunology
;
therapy
;
Drug Therapy, Combination
;
Humans
;
Immunoconjugates
;
therapeutic use
;
Immunologic Factors
;
adverse effects
;
therapeutic use
;
Immunosuppressive Agents
;
therapeutic use
;
Methotrexate
;
therapeutic use
;
Remission Induction
;
Tumor Necrosis Factor-alpha
;
antagonists & inhibitors